Cristina Sánchez-Puelles

Cristina Sánchez-Puelles

Auto-generated profile, based on publicly available information

Cristina Sánchez-Puelles

Department of Molecular, Cellular and Developmental Neurobiology, Cajal Institute, Consejo Superior de Investigaciones Científicas, 28002 Madrid, Spain

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 January 2016 in Nature Neuroscience
Verified
Journal Article
Closed access
PDF file
SKShira Knafo
Shira Knafo
CSCristina Sánchez-Puelles
Cristina Sánchez-Puelles
EPErnest Palomer
Ernest Palomer
IDIgotz Delgado
Igotz Delgado
JDJonathan E Draffin
Jonathan E Draffin
JEJose Esteban
Jose Esteban

21 February 2012 in PLOS Biology
Verified
Journal Article
Open access
PDF file
SKShira Knafo
Shira Knafo
CVCésar Venero
César Venero
CSCristina Sánchez-Puelles
Cristina Sánchez-Puelles
IPInmaculada Pereda-Peréz
Inmaculada Pereda-Peréz
AFAna Franco
Ana Franco
JEJosé A. Esteban
José A. Esteban
Cell adhesion molecules and downstream growth factor-dependent signaling are critical for brain development and synaptic plasticity, and they have been linked to cognitive function in adult animals. We have previously developed a mimetic peptide (FGL) from the neural cell adhesion molecule (NCAM) that enhances spatial learning and memory in rats. We have now investigated the cellular and molecular basis of this cognitive enhancement, using biochemical, morphological, electrophysiological, and behavioral analyses. We have found that FGL triggers a long-lasting enhancement of synaptic transmission in hippocampal CA1 neurons. This effect is mediated by a facilitated synaptic delivery of AMPA receptors, which is accompanied by enhanced NMDA receptor-dependent long-term potentiation (LTP). Both LTP and cognitive enhancement are mediated by an initial PKC activation, which is followed by persistent CaMKII activation. These results provide a mechanistic link between facilitation of AMPA receptor synaptic delivery and improved hippocampal-dependent learning, induced by a pharmacological cognitive enhancer. The human brain contains trillions of neuronal connections, called synapses, whose pattern of activity controls all our cognitive functions. These synaptic connections are dynamic and constantly changing in their strength and properties, and this process of synaptic plasticity is essential for learning and memory. Alterations in synaptic plasticity mechanisms are thought to be responsible for multiple cognitive deficits, such as autism, Alzheimer's disease, and several forms of mental retardation. In this study, we show that synapses can be made more plastic using a small protein fragment (peptide) derived from a neuronal protein involved in cell-to-cell communication. This peptide (FGL) initiates a cascade of events inside the neuron that results in the facilitation of synaptic plasticity. Specifically, we find that FGL triggers delivery of a specific type of glutamate receptor (AMPA receptors) to synapses in a region of the brain called the hippocampus, which is known to be involved in multiple forms of learning and memory. Importantly, when this peptide was administered to rats, their ability to learn and retain spatial information was enhanced. Therefore, this work demonstrates that cognitive function can be improved pharmacologically in adult animals by enhancing the plasticity of synaptic connections in the brain.

Verified
Journal Article
Open access
PDF file
MRMorgan Ramón-Landreau
Morgan Ramón-Landreau
CSCristina Sánchez-Puelles
Cristina Sánchez-Puelles
NLNoelia LOPEZ López-Sánchez
Noelia LOPEZ López-Sánchez
ALAnna Lozano-Ureña
Anna Lozano-Ureña
ALAina M. Llabrés-Mas
Aina M. Llabrés-Mas
José M. FradeJosé M. Frade
José M. Frade
E2F4 was initially described as a transcription factor with a key function in the regulation of cell quiescence. Nevertheless, a number of recent studies have established that E2F4 can also play a relevant role in cell and tissue homeostasis, as well as tissue regeneration. For these non-canonical functions, E2F4 can also act in the cytoplasm, where it is able to interact with many homeostatic and synaptic regulators. Since E2F4 is expressed in the nervous system, it may fulfill a crucial role in brain function and homeostasis, being a promising multifactorial target for neurodegenerative diseases and brain aging. The regulation of E2F4 is complex, as it can be chemically modified through acetylation, from which we present evidence in the brain, as well as methylation, and phosphorylation. The phosphorylation of E2F4 within a conserved threonine motif induces cell cycle re-entry in neurons, while a dominant negative form of E2F4 (E2F4DN), in which the conserved threonines have been substituted by alanines, has been shown to act as a multifactorial therapeutic agent for Alzheimer’s disease (AD). We generated transgenic mice neuronally expressing E2F4DN. We have recently shown using this mouse strain that expression of E2F4DN in 5xFAD mice, a known murine model of AD, improved cognitive function, reduced neuronal tetraploidization, and induced a transcriptional program consistent with modulation of amyloid-β (Aβ) peptide proteostasis and brain homeostasis recovery. 5xFAD/E2F4DN mice also showed reduced microgliosis and astrogliosis in both the cerebral cortex and hippocampus at 3-6 months of age. Here, we analyzed the immune response in 1 year-old 5xFAD/E2F4DN mice, concluding that reduced microgliosis and astrogliosis is maintained at this late stage. In addition, the expression of E2F4DN also reduced age-associated microgliosis in wild-type mice, thus stressing its role as a brain homeostatic agent. We conclude that E2F4DN transgenic mice represent a promising tool for the evaluation of E2F4 as a therapeutic target in neuropathology and brain aging.

31 December 2021 in Alzheimer's & Dementia
Verified
Journal Article
Closed access
PDF file
CSCristina Sánchez‐Puelles
Cristina Sánchez‐Puelles
GPGertrudis Perea
Gertrudis Perea
JFJose María Frade
Jose María Frade

5 September 2022 in Preprints.org
Verified
Preprint
Open access
PDF file
MRMorgan Ramón-Landreau
Morgan Ramón-Landreau
CSCristina Sánchez-Puelles
Cristina Sánchez-Puelles
NLNoelia LOPEZ López-Sánchez
Noelia LOPEZ López-Sánchez
ALAnna Lozano-Ureña
Anna Lozano-Ureña
ALAina M. Llabrés-Mas
Aina M. Llabrés-Mas
José M. FradeJosé M. Frade
José M. Frade
E2F4 was initially described as a transcription factor with a key function in the regulation of cell quiescence. Nevertheless, a number of recent studies have established that E2F4 can also play a relevant role in cell and tissue homeostasis as well as tissue regeneration. For these non-canonical functions, E2F4 can also act in the cytoplasm, where it is able to interact with many homeostatic and synaptic regulators. Since E2F4 is expressed in the nervous system, it may fulfill a crucial role in brain function and homeostasis, being a promising multifactorial target for neurodegenerative diseases and brain aging. The regulation of E2F4 is complex as it can be chemically modified through acetylation, from which we present evidence in the brain, as well as methylation, and phosphorylation. The phosphorylation of E2F4 within a conserved threonine motif induces cell cycle re-entry in neurons, while a dominant negative form of E2F4 (E2F4DN), in which the conserved threonines have been substituted by alanines, has been shown to act as a multifactorial therapeutic agent for Alzheimer’s disease (AD). We have generated transgenic mice neuronally expressing E2F4DN. We have recently shown using this mouse strain that expression of E2F4DN in 5xFAD mice, a known murine model of AD, improved cognitive function, reduced neuronal tetraploidization, and induced a transcriptional program consistent with modulation of amyloid-beta (Abeta) peptide proteostasis and brain homeostasis recovery. 5xFAD/E2F4DN mice also showed reduced microgliosis and astrogliosis in both cerebral cortex and hippocampus at 3-6 months of age. Here we have analyzed the immune response in 1 year-old 5xFAD/E2F4DN mice, concluding that reduced microgliosis and astrogliosis is maintained at this late stage. In addition, the expression of E2F4DN also reduced age-associated microgliosis in wild-type mice, thus stressing its role as a brain homeostatic agent. We conclude that E2F4DN transgenic mice represent a promising tool for the evaluation of E2F4 as a therapeutic target in neuropathology and brain aging.

5 November 2023 in IBRO Neuroscience Reports
Verified
Journal Article
Open access
AUAnna Lozano Ureña
Anna Lozano Ureña
AMAina Maria Llabrés Mas
Aina Maria Llabrés Mas
MRMorgan Ramón-Landreau
Morgan Ramón-Landreau
CSCristina Sánchez-Puelles
Cristina Sánchez-Puelles
VDVanesa Cano Daganzo
Vanesa Cano Daganzo
José M. FradeJosé M. Frade
José M. Frade